bf/NASDAQ:RXDX_icon.jpeg

NASDAQ:RXDX

Prometheus Biosciences, Inc.

  • Stock

199.92

+0.09%

0.18

USD last updated 03/08 01:57:01

Last Close

199.74

15/06 20:00

Market Cap

9.56B

Beta: −0.60

Volume Today

1.79M

Avg: 983.04K

PE Ratio

−63.62

PFCF: −88.63

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative ...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -1.5-1-0.52014-12-312015-12-312016-12-312020-03-302021-11-12

    Revenue (Estimate*)

    1M2M3M4M2014-12-312015-12-312016-12-312020-03-302021-11-12

    *Estimate based on analyst consensus